Evidence-Based Practice: Temozolomide Beyond Glioblastoma
- 5 March 2019
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Oncology Reports
- Vol. 21 (4), 30
- https://doi.org/10.1007/s11912-019-0783-5
Abstract
Purpose of ReviewTemozolomide is a first-line treatment for newly diagnosed glioblastoma. In this review, we will examine the use of temozolomide in other contexts for treating gliomas, including recurrent glioblastoma, glioblastoma in the elderly, diffuse low- and high-grade gliomas, non-diffuse gliomas, diffuse intrinsic pontine glioma (DIPG), ependymoma, pilocytic astrocytoma, and pleomorphic xanthoastrocytoma.Recent FindingsTemozolomide improved survival in older patients with glioblastoma, anaplastic gliomas regardless of 1p/19q deletion status, and progressive ependymomas. Temozolomide afforded less toxicity and comparable efficacy to radiation in high-risk low-grade gliomas and to platinum-based chemotherapy in pediatric high-grade gliomas.SummaryThe success of temozolomide in promoting survival has expanded beyond glioblastoma to benefit patients with non-glioblastoma tumors. Identifying practical biomarkers for predicting temozolomide susceptibility, and establishing complementary agents for chemosensitizing tumors to temozolomide, will be key next steps for future success.Keywords
This publication has 72 references indexed in Scilit:
- Adult Brainstem GliomasThe Oncologist, 2012
- Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology GroupNeuro-Oncology, 2011
- Bevacizumab and dose-intense temozolomide in recurrent high-grade gliomaAnnals of Oncology, 2010
- Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE StudyJournal of Clinical Oncology, 2010
- Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastomaNeuro-Oncology, 2010
- Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine gliomaNeuro-Oncology, 2008
- Temozolomide in pediatric low‐grade gliomaPediatric Blood & Cancer, 2007
- Temozolomide in Children with progressive low-grade glioma1Neuro-Oncology, 2007
- Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)British Journal of Cancer, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005